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Following this model, WHO anticipates that the use of Watch Group and Reserve Group antibiotics will be drastically reduced.
Reduction in the use of antibiotics represents a huge challenge in India, which is a major drug producer and has some of the highest sales of antibiotics globally and highest levels of antimicrobial resistance. 4 Contributing factors to these high sales include failures of India's drug regulatory system (which have been identified in government reports 5 ), the sale of antibiotics without prescription, and the proliferation of fixed-dose combination (FDC) antibiotics, many of which are not approved in other countries or by India's national regulator, the Central Drugs Standard Control Organization (CDSCO). FDCs are formulations comprising two or more drugs combined in a fixed ratio of doses and available in a single dosage form. FDCs that are composed of two antimicrobial drugs, especially drugs with mismatched dosing regimens, are concerning in the context of antimicrobial resistance, but few data are available on their use in low-income and middle-income countries.
We analysed 6 systemic antibiotic sales in India between 2007 and 2012 using previously reported methods and data sources that captured prescription and non-prescription sales and regulatory approval status. We investigated the formulations that were sold and categorised them according to whether they were FDCs or singledrug formulations (SDFs), their WHO classification, CDSCO approval status, and approval in the UK and USA. We excluded antituberculosis and primary antiviral or antifungal formulations. For FDC antibiotics, we investigated sales of formulations composed of two antimicrobial drugs. Our findings highlight serious hurdles for controlling antimicrobial resistance in India.
In India, total systemic antibiotic sales increased by 26% from 2056 million Units (where a Unit is a strip of ten tablets or capsules, or one bottle or vial of an oral liquid or injection) in 2007-08, to 2583 million in 2011-12. The increase was due to the growth in sales of FDCs, which rose by 38%, whereas sales of SDFs increased by 20%. By 2011-12, FDCs comprised 34% (872 million Units), and SDFs 66% (1711 million Units), of total sales in India.
When The changes needed to achieve the WHO vision of good use and stewardship of antibiotics are feasible. Obvious practical steps are to ban the sale of unapproved FDC antibiotics and to enforce existing regulations to prevent unapproved and illegal drugs reaching the market. The Indian Government has been unsuccessful on both counts. Although it has acknowledged the problems, commissioned reports, and banned some unapproved FDCs-including antibiotics-in 2007 and 2016, the bans were challenged and remain unresolved in the courts while the FDCs in question apparently remain on the market. Aside from regulatory measures, appropriate changes in antibiotic use would be assisted by improved access to health care to reduce non-prescription sales. Additionally, research is needed to understand why doctors complicate problems by prescribing unapproved antibiotic FDCs.
